

Client:	Location:	☐ RE-TEST ☐ Employee ☐ Family
---------	-----------	-------------------------------

## COVID-19 IgG/IgM Antibodies & RT-PCR Test Request Form

Please complete this form a	and pr	ovide patient'	's insur	anc	e card and pe	erson	nal identif	cation	າ at time	of collection.	
LABORATORY PERSONNEL – FO	OR OF	FICE USE ONI	LY								
Today's Date:	Init	Initials:			Location Na	cation Name:					
Clinician Name:	Tim	Time:			Phone:						
PATIENT INFORMATION: COMPLETED BY PATIENT OR PARENT/GUARDIAN											
First Name:		Last Name:						3:		Age:	
Address:		·						Phone:			
City:		State: Zip Co			de:				Male	□ Female	
EMAIL (PRINT CLEARLY):											
Does the patient live or work in a congregate setting (i.e.: long-term care facility, shelter, group home, prison and/or jail)											
□ YES □ NO	Fac	ility Name:			Er	nploy	ployee Occupation:				
Does the patient receive dialysis?   VES   NO											
TYPE OF INSURANCE:											
□ PPO □ HMO □ KAISER PERMANENTE □ MEDICARE □ MEDI-CAL (MEDICAID) □ UNINSURED PROGRAM □ CASH											
CLINICAL INFORMATION: COM	1PLET	ED BY PATIEN	NT								
Date of symptom onset:		□ None		Doe	es the patient l	nave a	any underly	ying co	nditions?	YES □ NO	
SYMPTOMS OBSERVED:		□ N	lone		П	Immu	nocompro	omised			
□ Fever □ Runny nose			Inknown			Pregna	=	Jillisea			
☐ Tiredness ☐ Loss of smell			□ Diabetes □ Chronic Lung Disease								
□ Dry Cough □ D	□ Diarrhea			□ Hypertension □ Chronic Liver Disease							
	oss of A	s of Appetite			□ Cardiac Disease □ Chronic Kidney Disease						
□ Nasal Congestion □ O	asal Congestion    Other:		□ Other:								
LABORATORY TESTING – COMPLETED BY PATIENT											
Has the nationt been tested for influence 2					Result:		□ Positive		□ Negativ	ve	
Has the patient been tested for influenza? ☐ YES ☐ NO				Test Typ	e:	□ Rapid		□ PCR			
Has the patient been tested for any other viral respiratory illness?				□ YES □ NC	)	If yes,	result:				
COVID 19 TESTING – COMPLETED BY PATIENT											
Has the patient been tested for COVID-19? □ YES □ NO				Result:		□ Positive		□ Negativ	ve		
					Test Typ		□ Rapid		□ PCR		
I hereby acknowle	edge	•			-				_	-	
TEST: □ RT-PCR □ SARS-Cov2 IgG Antibody □ SARS-Cov2 IgM Antibody											
SOURCE:		Anterior N	asal Sv	vab		) (Na	ısopharyı	ngeal	Swab)		
hereby acknowledge full and complete consent to and may phlebotomy services. I hereby request and authorize ic., to collect this sample for me or the person named roviders, subcontractors, successors, agents, their respend all liability, injury or damage whatsoever arising from egligence. I authorize my medical information herein, i pur personal and health information to treat you, to receivities we perform to improve quality care. We have erronal health information. I acknowledge that I have tumples. Please provide a copy of this form to your phrofessional. PMH Laboratory, Inc., is not providing you	PMH Lab above for ctive insur- m, or in ar neluding to receive payr prepared a received a sysician a	oratory, Inc. designate whom I am the legal rance carriers, and the ny way connected with tests results, to be shar ment for the care we pa detailed NOTICE O copy of the Notice of nd/or healthcare proving the state of the care we can be compared to the care we pa detailed NOTICE O copy of the Notice of nd/or healthcare proving the care was a constant.	ed subcontral guardian. location span, this SARS red with my provide, to DF PRIVAC f Privacy and vider for years.	actor I here consor S-CoV phys public CY A nd Co our n	who is an independently release PMH Laling this clinic/progration of the properties of the properties of the properties of the properties as ND CONFIDENTL on fidentiality Practice redical records. This	oratory am, its p Antibod loyer/sol required ALITY es. I agres test is	whealthcare stary, Inc. its principalis, directly Test or the about hool/organization, and for our of PRACTICES are to remain in for information	ffing ager ipals, dire tors, emp idministra on or grou ther healt to help y the gene al purpose	ney, not direct ectors, member oloyees, affilia tion of same in the care operate to better under areal area for at es only and to	tly affiliated with PMH lers, employees, affiliates ates, successors, or agent including, but not limited boratory, Inc., will use a tions which generally interstand our policies reget t least 5 minutes after to be discussed with your	Laborator s, supplier tts from an d to, acts of and disclost actude those arding you offection of health can

are immune or cannot become re-infected. This test was developed, and its performance characteristics determined by PMH Laboratory, Inc. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test has been validated in accordance with the FDA's Guidance Document (Policy for Diagnostics Testing in Laboratories Certified to Perform High Complexity Testing under CLIA prior to Emergency Use Authorization for Coronavirus Disease-2019 during the Public Health Emergency) issued on April 20, 2020. FDA independent review of this validation is pending. This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

PATIENT/GUARDIAN SIGNATURE: DATE:	
-----------------------------------	--